Thursday, September 25, 2014

Trading Opportunity - Tonix Pharmaceuticals (TNXP)

Tonix Pharmaceuticals is due to report top line results in it's pivotal, phase 3 trial of it's lead compound, TNX-102,  as a treatment of Fibromyalgia.   The compound is a reformulated delivery of cyclobenzaprine (many of us with back pain know it as flexiril) which allows the drug to be delivered directly into the blood stream by placing the pill under the tongue.

The market isn't giving it much of a chance with a market cap of only $131 million as of the time of this post but the stock appreciation upside is massive if the results come back positive.  If negative, you will see just the opposite result as there isn't much of a pipeline outside of TNX-102.

I've got 1,000 shares and I may add another 1,000 tomorrow and roll the dice for positive results.

Good luck on your biotech investments and hope everyone has a great weekend!


No comments:

Post a Comment

Thank you for your contribution to BiotechInvestor.com